Gene therapy

Axovia Therapeutics, a gene therapy company developing disease-transformative medicines for ciliopathies, led by researcher Professor Philip Beales, has launched after being in stealth mode for the past year. Axovia is a majority-owned subsidiary of Jaguar Gene Therapy, and is partially funded by UCL Technology Fund. Axovia is receiving initial operational support from Jaguar Gene Therapy, […]

Bluebird Bio has placed its Phase I/II (HGB-206) and Phase III (HGB-210) studies of LentiGlobin gene therapy for sickle cell disease (SCD) (bb1111) on a temporary suspension due to a reported Suspected Unexpected Serious Adverse Reaction (SUSAR) of acute myeloid leukaemia (AML). In line with the clinical study protocols for HGB-206 and HGB-210, the company […]

Today’s episode is titled: The power of precision and the potential of human tissue chips, and covers 2 articles taken from the most recent issue of DDW. These articles are titled: The power of precision to keep biologics effective and safe & Why we should be interested in human tissue chips These articles were written by Dr Mark […]

By Akash Bhattacharya, Senior Application Scientist at Beckman Coulter Life Sciences Gene therapy holds enormous potential to cure and prevent a range of diseases, from inherited disorders to cancers to viral infections. The first gene therapy product was approved by the Food and Drug Administration in the US in 2017, and since then, approvals have […]

Cobra Biologics, the gene therapy division of the Cognate BioServices’ group, has announced a multi-phase expansion of its plasmid DNA services, a continuation of its gene therapy services’ project for viral vectors and plasmid DNA. This includes a four-fold increase in HQ High Quality (HQ) DNA manufacturing capacity alongside new clinical and commercial GMP DNA […]

The Cell and Gene Therapy Catapult (CGT Catapult) and Hertfordshire Local Enterprise Partnership (LEP) in the UK have announced that a new cell and gene therapy integration laboratory at the CGT Catapult facility in Stevenage will be part-funded by the government’s Getting Building Fund. The new laboratory will be exclusively dedicated to the provision of […]

The Jefferies Healthcare Temperature Check report is now in its third edition and published to coincide with the 11th annual Global Healthcare Conference which was held virtually. Over 500 responses from senior leaders in the sector responded for this year’s report, giving views on both the current state of the market and predictions for 2021. […]

CEVEC Pharmaceuticals has signed an option and license agreement with Roche for the use of its newly launched ELEVECTA Technology for large scale manufacturing of adeno‐associated virus (AAV) vectors for gene therapy applications. Under the terms of the agreement, CEVEC will grant Roche, and Spark Therapeutics, a member of the Roche Group, an option for […]

Oxford Biomedica, gene and cell therapy group and PhoreMost, the UK-based biopharmaceutical company dedicated to developing drugs against intractable disease targets, have entered into a discovery collaboration to develop next-generation CAR-T cell therapies. Financial details of the agreement are not disclosed. PhoreMost will deploy its in-house expertise and next-generation phenotypic screening platform, Siteseeker, to identify […]

Lonza will be hosting a free webinar to discuss its innovative approach to digitalising the company’s cell and gene therapy manufacturing operations through the implementation of the MODA-ESTM Platform. It will take place on 17 November. In the webinar, Lonza will also outline future plans for utilising the platform to eliminate bottlenecks and achieve operational […]